Compile Data Set for Download or QSAR
Report error Found 36 Enz. Inhib. hit(s) with all data for entry = 808
TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292056(US10100045, Example 27 | 2-Cyclobutyl-3-(7-methyl-...)
Affinity DataIC50: 0.0200nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292057(US10100045, Example 28 | 3-(7-Chloro-1H-indazol-5-...)
Affinity DataIC50: 0.0200nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292055(US10100045, Example 26 | 7-Chloro-5-(2-cyclobutyl-...)
Affinity DataIC50: 0.0320nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292054(US10100045, Example 25 | 5-(2-Cyclobutyl-5-(triflu...)
Affinity DataIC50: 0.0500nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292053(US10100045, Example 24 | 3-(7-Chloro-1H-indazol-5-...)
Affinity DataIC50: 0.0630nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292061(US10100045, Example 34 | 5-(Difluoromethyl)-2-isop...)
Affinity DataIC50: 0.100nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292037(US10100045, Example 8 | 2-Cyclopentyl-3-(7-methyl-...)
Affinity DataIC50: 0.126nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292065(US10100045, Example 40 | 5,7-Bis(difluoromethyl)-2...)
Affinity DataIC50: 0.158nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292052(US10100045, Example 23 | 2-Isopropyl-3-(7-methyl-1...)
Affinity DataIC50: 0.251nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292051(US10100045, Example 22 | 7-Chloro-5-(2-isopropyl-5...)
Affinity DataIC50: 0.251nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292045(US10100045, Example 16 | 3-(7-Chloro-1H-indazol-5-...)
Affinity DataIC50: 0.316nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292062(US10100045, Example 36 | 7-Chloro-5-(5-(difluorome...)
Affinity DataIC50: 0.398nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292050(US10100045, Example 21 | 5-(2-Isopropyl-5-(trifluo...)
Affinity DataIC50: 0.398nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292049(US10100045, Example 20 | 3-(7-Chloro-1H-indazol-5-...)
Affinity DataIC50: 0.398nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292059(US10100045, Example 30 | 2-(Difluoromethyl)-3-(7-m...)
Affinity DataIC50: 0.631nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292060(US10100045, Example 31 | 3-(7-Chloro-1H-indazol-5-...)
Affinity DataIC50: 0.631nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292041(US10100045, Example 12 | 2-Cyclobutyl-3-(1H-indazo...)
Affinity DataIC50: 0.631nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292048(US10100045, Example 19 | 2-Ethyl-3-(7-methyl-1H-in...)
Affinity DataIC50: 0.794nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292044(US10100045, Example 15 | 2-Methyl-3-(7-methyl-1H-i...)
Affinity DataIC50: 1nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292032(US10100045, Example 3 | 5-[2-(Difluoromethyl)-5-(t...)
Affinity DataIC50: 1nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292038(US10100045, Example 9 | 5-(2-Phenyl-5-(trifluorome...)
Affinity DataIC50: 1.58nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292047(US10100045, Example 18 | 7-Chloro-5-(2-ethyl-5-(tr...)
Affinity DataIC50: 2.51nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292058(US10100045, Example 29 | 7-Chloro-5-(2-(difluorome...)
Affinity DataIC50: 2.51nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292040(US10100045, Example 11 | 3-(1H-Indazol-5-yl)-2-phe...)
Affinity DataIC50: 3.16nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292046(US10100045, Example 17 | 5-(2-Ethyl-5-(trifluorome...)
Affinity DataIC50: 5.01nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292039(US10100045, Example 10 | 5-(2-Phenyl-5-(trifluorom...)
Affinity DataIC50: 6.31nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292031(US10100045, Example 2 | 7-Methyl-5-(2-methyl-5-(tr...)
Affinity DataIC50: 12.6nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292036(US10100045, Example 7 | 5-(2-Cyclopentyl-5-(triflu...)
Affinity DataIC50: 15.8nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292034(US10100045, Example 5 | 5-(2-Isopropyl-5-(trifluor...)
Affinity DataIC50: 25.1nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292064(US10100045, Example 39 | 3-(7-Chloro-1H-indazol-5-...)
Affinity DataIC50: 63.1nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292033(US10100045, Example 4 | 5-(2-Ethyl-5-(trifluoromet...)
Affinity DataIC50: 100nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292035(US10100045, Example 6 | 5-(2-(Cyclobutylmethyl)-5-...)
Affinity DataIC50: 126nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292043(US10100045, Example 14 | 3-(1H-Indazol-5-yl)-2-(py...)
Affinity DataIC50: 126nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292063(US10100045, Example 38 | 7-(Difluoromethyl)-2-isop...)
Affinity DataIC50: 126nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292030(US10100045, Example 1 | 5-(2-Methyl-5-(trifluorome...)
Affinity DataIC50: 316nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVoltage-dependent calcium channel gamma-2 subunit(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM292042(US10100045, Example 13 | 3-(1H-Indazol-5-yl)-2-(2-...)
Affinity DataIC50: 794nMpH: 7.4Assay Description:Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer...More data for this Ligand-Target Pair
In DepthDetails
US Patent